Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

ruxolitinib 1axatilimab 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bronchiolitis Obliterans Syndrome × ruxolitinib × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡